Can Response to Bedtime Insulin with Daytime Sulfonylurea Be Predicted in Patients with Type 2 Diabetes Mellitus?

1997 ◽  
Vol 13 (5) ◽  
pp. 200-205
Author(s):  
Julie C Oki ◽  
Alexander Tal ◽  
Leland Graves ◽  
William L Isley
Keyword(s):  
Diabetes Mellitus ◽  
Body Mass Index ◽  
Blood Glucose ◽  
Body Mass ◽  
Age Of Onset ◽  
Blood Glucose Concentration ◽  
Fasting Blood Glucose ◽  
Type 2 Dm ◽  
Hb Concentration

Objective: To determine characteristics predictive of response in patients with Type 2 diabetes mellitus (Type 2 DM) who demonstrate good or poor blood glucose control while receiving bedtime insulin with daytime sulfonylurea (BIDS) therapy. Methods: A retrospective chart review of patients with Type 2 DM receiving BIDS therapy was performed. The criterion for responders was the mean of two consecutively obtained glycosylated hemoglobin (Hb) concentrations being less than or equal to 10.2% (HbA1c ≤7.0%). Setting: A university-affiliated diabetes specialty clinic staffed consistently by a pharmacist diabetes educator, four endocrinologists, and a pharmacotherapy specialist. Patients: Thirty-one patients with Type 2 DM who were predominantly African-American and women who had documented regular follow-up examinations for more than 12 months while receiving BIDS therapy. Data Collection and Measurements: Gender, ethnicity, height, weight, calculated body mass index, age of onset of diabetes mellitus, duration of diabetes mellitus before BIDS therapy, pre-BIDS treatment regimen, dosages of NPH insulin and glyburide, glycosylated Hb concentration, fasting blood glucose concentration, and duration of BIDS therapy were recorded. Results: There were no differences in age of onset of diabetes mellitus, duration of diabetes mellitus before BIDS was initiated, duration of therapy with BIDS, or baseline glycosylated Hb concentration between responders (n = 15) and nonresponders (n = 16). Patients in the responder group weighed less, had a lower body mass index, required smaller dosages of both glyburide and NPH insulin, and achieved a lower fasting blood glucose concentration. Conclusions: In this study population, with the exception of body mass index, there was no difference in suggested clinical characteristics of response between responders and nonresponders.

scholarly journals Uji Efektivitas Beras Herbal Forte terhadap Penurunan Kadar Glukosa Darah Pasien Diabetes Melitus Tipe 2 (Study of the Herbal Rice Forte Effectiveness on Decreasing Blood Glucose of Diabetes Mellitus Type 2 Patient)

2018 ◽  
Vol 6 (1) ◽  
pp. 85
Author(s):  
Gema Akbar Wakhidana ◽  
Ancah Caesarina Novi Marchianti ◽  
Ali Santosa
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Treatment Group ◽  
Metabolic Diseases ◽  
Fasting Blood Glucose ◽  
Control Group ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Type 2 Dm

Diabetes mellitus is metabolic diseases characterized by hyperglycemia caused by disturbances in insulin secretion or insulin activity. Herbal Forte Rice is rice synthetic material composed of main purple sweet potato and corn flour. It contains antioksidan, fiber, resistant starch and having moderate glycemic index. This study aimed to determine the effectivity of Herbal Forte Rice on decreasing blood glucose levels of patients type 2 DM. It used a cross-over design, the role of research subjects was both as control and treatment groups. Total sample of this research consisted of 60 samples. The treatment group was given Herbal Forte Rice for 7 days in 2 consecutive meals, while the control group did not receive any intervention. The results showed the average level of Fasting Blood Glucose (FBG) beginning and end of the treatment group 179.76 mg/dL and 138.7 mg/dL; FBG beginning and end of the control 180.87 mg/dL and 187.63 mg/dL; 2 hours post prandial Blood Glucose (2hppBG) levels of beginning and end of the treatment group 284.37 mg/dL and 183.8 mg/dL; 2hppBG levels beginning and end of the control 280.57 mg/dL and 284.13 mg/dL. This study concludes that Herbal Forte Rice effective on decreasing blood glucose levels of patients type 2 DM.   Keywords: diabetes mellitus, Rice Herbal Forte, GDP and GD2PP  

scholarly journals The Relationship of Body Mass Index and Diabetic Foot Risk in Type 2 Diabetes Mellitus at Royal Prima Hospital on Period 2018 to 2020

2021 ◽  
Vol 2 (4) ◽  
pp. 201-205
Author(s):  
Emori Christina Simarmata ◽  
Tasya Armadinah ◽  
Yeni Puspawani ◽  
Juliana Lina
Keyword(s):  
Diabetes Mellitus ◽  
Body Mass Index ◽  
Body Mass ◽  
Diabetic Foot ◽  
Metabolic System ◽  
Simple Method ◽  
Type 2 Dm ◽  
Patients With Diabetes ◽  
Relationship Of

Body mass index (BMI) is a simple method that is commonly used to determine whether a person is obese or not.  Diabetes mellitus is a disorder of the metabolic system because the pancreas cannot produce enough insulin or the body's cells cannot use insulin effectively. Diabetic foot is one of the chronic complications of diabetes mellitus (DM). Diabetic foot begins with hyperglycemia which causes abnormalities in neuropathy and blood vessels, causing infection. To determine the proportion of body mass index in patients with diabetes mellitus, to determine the prevalence of diabetic feet and non-foots. The research design used in this study is observational analytic. There is a relationship between body mass index and the risk of diabetic foot in type 2 DM patients at Royal Prima Hospital. Prevalence of body mass index 23. 0 in DM Type 2 at Royal Prima Hospital Medan in 2018-2020 reached 70%. The prevalence of diabetic foot in Type 2 DM at the Royal Prima Hospital Medan in 2018-2020 reached 54%.

scholarly journals Efficacy and safety of bromocriptine quick release as an add on therapy with metformin and glipizide in type 2 diabetes mellitus patients: an open label randomized controlled study

2019 ◽  
Vol 8 (4) ◽  
pp. 669
Author(s):  
Nithyapriya M. ◽  
S. Purushotaman
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Postprandial Blood Glucose ◽  
Control Group ◽  
Study Group ◽  
Quick Release ◽  
Type 2 Dm

Background: Type 2 Diabetes Mellitus (DM) is a metabolic disorder, treated by insulin and oral hypoglycaemic agents (OHA). Despite treatment, to protect diabetic population from its complications is difficult. So, there is a need for an OHA with different mechanism of action and minimal side effects. Bromocriptine Mesylate QR (Quick release) formulation was approved by FDA for treatment of type 2 DM. Hence, this study was planned to highlight the usefulness of Bromocriptine QR in type 2 diabetes mellitus.Methods: Total 140 patients with type 2 DM were randomized into two groups. The control group was treated with Metformin 500 mg BD (twice daily) and Glipizide 5 mg BD for a period of 3 months. The study group received Bromocriptine quick release 1.6 mg once daily, metformin 500 mg BD and Glipizide 5 mg BD for a period of 3 months. In both control and study groups, fasting blood glucose, postprandial blood glucose was monitored at 0, 1st, 2nd and 3rd month. HbA1C was done at baseline and at the end of 3 months.Results: There was statistically significant decrease in fasting blood glucose, postprandial blood glucose and HbA1C when compared to baseline in both control group (p <0.05) and study group (p <0.05) at the end of 3 months. But the decrease in FBS, PPBS, HbA1C was higher in the study group (p=0.0001) than the control group (p=0.001).Conclusions: In type 2 DM patients, Bromocriptine QR, combined with metformin and Glipizide reduced fasting and postprandial blood glucose and HbA1C significantly compared to metformin and glipizide alone.

Impact of Body Mass Index on Fasting Blood Glucose Concentration among Helicobacter pylori Carriers

2003 ◽  
Vol 21 (3) ◽  
pp. 262-265 ◽  
Author(s):  
Ioannis D. Kyriazanos ◽  
Ioannis Sfiniadakis ◽  
Panagiotis Dimakos ◽  
Vasilios Gizaris ◽  
Konstantinos Datsakis ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Helicobacter Pylori ◽  
Blood Glucose ◽  
Body Mass ◽  
Glucose Concentration ◽  
Blood Glucose Concentration ◽  
Fasting Blood Glucose ◽  
Fasting Blood Glucose Concentration

scholarly journals Profil penggunaan obat antidiabetes pada pasien diabetes mellitus tipe 2 di instalasi rawat jalan RSUD Provinsi NTB tahun 2018

2021 ◽  
Vol 2 (1) ◽  
pp. 37-41
Author(s):  
Baiq Sofianti Annisa ◽  
Candra Eka Puspitasari ◽  
Siti Rahmatul Aini
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Regular Insulin ◽  
Cross Sectional ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Type 2 Dm ◽  
Aspart Insulin

Diabetes mellitus (DM) is a disorder of insulin secretion, insulin action or both, which are characterized by blood glucose levels 200 mg/dl and / or fasting blood glucose levels 126 mg/dl. In 2017 Indonesia was recorded as the sixth largest country with DM in the world. The most common classification of diabetes is type 2 DM with an incidence 90-95%. The study aimed to determine the profile of antidiabetic use in type 2 DM patients at the outpatient installation of RSUD Provinsi NTB in 2018. This study used cross sectional design retrospectively with purposive sampling method for the period January-December 2018. The results showed that in 112 patients, 195 antidiabetic agents were prescribed. The antidiabetic prescribed were metformin (33.85%), glimepirid (25.13%), aspart insulin (13.33%), insulin detemir (8.21%), pioglitazone (6.67%), insulin glargine (6.67%), glyclazide (1.54%), gliquidone (1.54%), acarbose (1.54), regular insulin (1.03%), and insulin lispro (0.51%). Overall, antidiabetic use was in accordance with the guideline recommendations. Further research is needed regarding the review of prescriptions and detailed indications in order to increase rationality of drug use, reduce morbidity and mortality and reduce medical costs.

scholarly journals DOSE-DEPENDENT EFFECTS OF HABITUAL COFFEE AND TEA CONSUMPTION ON SOME RISK FACTORS OF TYPE 2 DIABETES MELLITUS IN LIBYA

2020 ◽  
Vol 8 (12) ◽  
pp. 488-494
Author(s):  
Rehab R. Walli ◽  
◽  
Amal A. Ammar ◽  
Eman S. Moftah ◽  
Asma M. Eswayah ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Body Mass Index ◽  
Blood Glucose ◽  
Green Tea ◽  
Body Mass ◽  
Fasting Blood Glucose ◽  
Black Tea ◽  
Blood Cholesterol ◽  
Tea Consumption

Patients Lifestyle such as habitual consumption of certain meals and beverages plays major role in the development of diabetes. There is strong positive association between overall obesity as measured by Body Mass Index (BMI), blood cholesterol, blood pressure and diabetes. Black and green tea and coffee are traditional beverages that are daily consumed by many Libyans. In this study, we studied the relationship between the average daily consumed amount of coffee, green tea, or black tea and fasting blood glucose, cholesterol, blood pressure or Body Mass Index (BMI) as an indicator for obesity in type 2 diabetic patient. Our study included 396 Libyan diabetic patients (292 females and 104 males) with mean age of 49±17 years from Tripoli center of diabetes. This study performed during a period of 2 years. We also included control patients who were coffee or tea non consumer type2 diabetics. The results of this study showed that as the amount of daily consumed coffee, green tea, and black tea increases there is a marked decrease in fasting blood glucose of type 2 diabetics. In addition, a habitual green tea consumption strongly reduces blood cholesterol, blood pressure and BMI while black tea has weaker effect. In contrast, coffee consumption significantly increases blood cholesterol, BMI and blood pressure of diabetics at higher doses.

scholarly journals Correlation between Plasma Osteopontin and Alkaline Phosphatase in Type 2 Diabetes Mellitus Patients

2020 ◽  
Vol 26 (2) ◽  
Author(s):  
Josua TH Sinambela ◽  
M.I Diah Pramudianti ◽  
Dian Ariningrum
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Alkaline Phosphatase ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Postprandial Blood Glucose ◽  
P Value ◽  
Healthy Controls ◽  
Type 2 Dm

Diabetes Mellitus (DM) is a chronic disease caused by pancreas the inability to produce insulin or ineffectively insulin use.Fracture risk in type 2 DM patients increases even though the bone density is normal. This study aimed to examine thecorrelation of osteopontin (OPN) and alkaline phosphatase (ALP) in type 2 DM patients. An observational analytical studywas conducted in 73 type 2 DM patients in Dr. Moewardi Hospital, Surakarta from October to November 2018. The subjectswere examined for blood pressure, fasting blood glucose, two hours postprandial blood glucose, HbA1c, OPN, and ALPlevels. P-value <0.05 was statistically significant with a 95% confidence interval. Poorly controlled type 2 DM had higher OPNlevels than well-controlled (20.5±2.8 vs. 14.8±3.1 ng/mL, p <0.001). The ALP concentration was also higher in poorlycontrolled type 2 DM patients (79.9±31.7 vs. 61.1±25 U/L, p=0.003). The levels of OPN and ALP were significantly correlatedin type 2 diabetes (r=0.273; p=0.020) and in well-controlled patients (r=0.353; p=0.047) but no correlation was found inpoorly controlled type 2 DM patients (r= -0.073; p= 0.652). In this study, a significant correlation was found between OPNand ALP in patients with type 2 DM and well-controlled. Further study involving healthy controls and bone ALPmeasurement is needed.

scholarly journals NCEP-ATP III and IDF criteria for metabolic syndrome predict type 2 diabetes mellitus

2016 ◽  
Vol 35 (1) ◽  
pp. 46 ◽  
Author(s):  
Eva Sulistiowati ◽  
Marice Sihombing
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Cohort Study ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Screening Programs ◽  
Type 2 Dm

<p><strong>Background</strong><strong></strong></p><p>Subjects with metabolic syndrome (MetS) have a greater risk for acquiring type 2 diabetes mellitus (type 2 DM). The MetS criteria usually used are those of the National Cholesterol Education Program Expert Panel (NCEP) and Adult Treatment Panel III (ATP III) and of the International Diabetes Federation (IDF). This study aimed to evaluate the modified NCEP-ATP III and IDF criteria as predictor of type 2 DM among subjects with MetS.</p><p> </p><p><strong>Methods</strong></p><p>A cohort study was conducted among 4240 subjects with MetS. MetS was determined according to the modified NCEP-ATP III and IDF criteria. The study followed up 3324 non-diabetic subjects of the cohort study of non-communicable disease (NCD) risk factors (NCD study) during a 2-year period. Type 2 DM was determined from the diagnosis by health personnel or from fasting blood glucose of ≥126 mg/dL or blood glucose of ≥200 mg/dL, 2 hours after 75g glucose loading.</p><p> </p><p><strong>Results</strong></p><p>The MetS prevalence based on modified NCEP ATP III and IDF criteria in non-DM subjects was 17.1% and 15.6%, respectively. The risk for DM in subjects with MetS using modified NCEP ATP III and IDF criteria was 4.7 (CI 95%: 3.4-6.5) and 4.1 (CI 95%: 3.0-5.7), respectively.</p><p> </p><p><strong>Conclusions</strong></p><p>Both MetS criteria can be used as predictors of the occurrence of DM type 2, but the modified NCEP-ATP III is more properly applied than the IDF criteria in subjects with MetS. Screening programs and routine monitoring of MetS components are required for early detection of type 2 DM.</p>

Sign in / Sign up

Export Citation Format

Share Document